Watch our 2022 National Annual Meeting, during which President and CEO, Michael Boyle, MD, and Foundation panelists, discussed progress made in 2021 and shared their vision for 2022 in cure, care, and community. Panelists included Whitney Brown, MD, senior director of clinical affairs; JP Clancy, MD, VP of clinical research; Tony Durmowicz, MD, VP of clinical development; Bruce Marshall, MD, EVP and chief medical officer; and Sue Sullivan, head of community partnerships. Originally recorded January 27, 2022. 0:00 | National Annual Meeting - 2022 1:20 | Thank you to the cystic fibrosis community and supporters 2:42 | Highlights from 2021 12:20 | CF community voices video 19:12 | Where are we with genetic therapy research? What is ahead for people with rare and nonsense CF mutations? 27:00 | How are we working with the CF community in clinical trials? 30:32 | What is happening with modulators and CF care? 35:19 | Can you give an update on the PROMISE study? 37:35 | What’s happening with the development of other CFTR modulators? 39:25 | Can you provide an update on transplant and advanced CF lung disease? 42:38 | What have been the effects of COVID-19 on care? 45:11 | How are we taking care of the whole person with CF? 47:36 | What’s next for research into infections? 51:56 | What’s happening in phage therapy research? 53:14 | How are we reaching people with CF who are underserved or unconnected, and why is it important? 55:07 | Should someone post-transplant ask their doctor about taking Trikafta? 56:50 | Is there anything happening in nontuberculous mycobacteria (NTM) infections? 59:48 | What’s happening in gastrointestinal (GI) health and liver disease work? 1:01:46 | What’s the latest on research into splice mutations? 1:03:57 | Are there other ways to help gather the CF community besides BreatheCon? 1:05:06 | Theme for 2022 and closing